You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

riTUXimab (subcut)

( rit-TUCKS-ee-mab )
Funding:
New Drug Funding Program
  • Rituximab (SC) - Aggressive Histology Lymphoma
  • Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
  • Rituximab (SC) - Maintenance Treatment - Lymphoma
  • Rituximab (SC) - Retreatment - Indolent Lymphoma
  • Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
  • Rituximab (SC) - Second Line - Chronic Lymphocytic Leukemia
  • Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia
Other Name(s): Rituxan® SC
Appearance: Clear, colourless to yellowish solution

Drug Monograph

Sep 2019

Patient Info Sheet

Jul 2018

What it is used for

  • For treating blood cancers such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL)


You might also be interested in